Contact Us
Drug Search Results
More Filters [+]

Sodium picosulfate

Alternative Names: sodium picosulfate, picosulfate sodium, picolax, sodium picosulphate, pico-salax, picoprep, clenpiq, prepopik
Latest Update: 2024-11-19
Latest Update Note: Clinical Trial Update

Product Description

Sodium picosulfate is in a class of medications called stimulant laxatives (Sourced from: https://medlineplus.gov/druginfo/meds/a613020.html)

Mechanisms of Action: Peristalsis Agonist,Mucosa Agonist

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Brazil | Bulgaria | Canada | Chile | China | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam

Approved Indications: None

Known Adverse Events: None

Company: Ferring
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Sodium picosulfate

Countries in Clinic: United States

Active Clinical Trial Count: 1

Highest Development Phases

Phase 2: Other

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
PICCOLO

P2

Recruiting

Other

2026-03-01

24%
PICCOLO

P2

Recruiting

Other

2026-03-01

24%
PICCOLO

P2

Recruiting

Other

2026-03-01

24%

Recent News Events

Date

Type

Title

10/05/2023

News Article

 Ironwood to Present New Data at NASPGHAN Annual Meeting Reinforcing Impact of Linaclotide on Functional Constipation in Children and Adolescents Ages 6-17 Years-Old

05/24/2022

News Article

 Motus GI Announces Positive Topline Data From EU Study of the Pure-Vu System in Hard-to-Prepare Patients Presented at Digestive Disease Week 2022

04/21/2022

News Article

 Motus GI Completes Enrollment in the European Union Feasibility Study of the Pure-Vu® System as a New Method for Bowel Cleansing in Patients with a History of Poor Bowel Preparation

09/08/2021

News Article

 Motus GI Announces Enrollment of Patients at Second Site in the European Union Outpatient Study of the Pure-Vu® System

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions